Most Read Articles
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 27 May 2020

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates. 

Pank Jit Sin, 14 Apr 2020
With the movement control order (MCO) in full gear, most conferences and meetings are being postponed or cancelled. Some have taken to having conferences and meetings in a virtual setting, such as the recently ended American College of Cardiology/World Congress of Cardiology (ACC.20/WCC) conference. MIMS and the Asian Young Pharmacist Group (AYPG) took this opportunity to engage with pharmacists in the form of a Zoom meeting. 

Fezolinetant a viable nonhormone therapy for menopausal vasomotor symptoms

29 Mar 2020

The selective neurokinin 3 receptor antagonist fezolinetant induces rapid reductions in moderate-to-severe menopausal vasomotor symptoms (VMS) with a tolerable safety profile, according to the results of a phase IIb trial.

A total of 352 women aged 40 to 65 years with moderate-to-severe VMS (≥50 episodes/week) were randomized to receive 12 weeks of treatment with fezolinetant 15, 30, 60 or 90 mg twice daily, or 30, 60 or 120 mg once daily, or placebo. Of these women, 287 completed the trial.

Primary outcomes examined were decreases in VMS frequency and severity (calculated as follows: [number of moderate VMS × 2] + [number of severe VMS × 3]/total daily moderate-to-severe VMS) at weeks 4 and 12. The key secondary outcome was response (≥50-percent reduction in moderate-to-severe VMS frequency).

Compared with placebo, fezolinetant reduced moderate-to-severe VMS frequency by −1.9 to −3.5/day at week 4 and by −1.8 to −2.6/day at week 12 (p<0.05 vs placebo). Mean difference in VMS severity score vs placebo was −0.4 to −1 at week 4 (p<0.05 for all doses) and −0.2 to −0.6 at week 12 (p<0.05 for 60 and 90 mg BID and 60 mg QD).

Response was achieved by 81.4 percent to 94.7 percent of participants with fezolinetant vs 58.5 percent with placebo at the end of treatment (p<0.05 for all doses).

Treatment-emergent adverse events (TEAEs) were mostly mild to moderate, and there were no serious TEAEs documented.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 27 May 2020

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates. 

Pank Jit Sin, 14 Apr 2020
With the movement control order (MCO) in full gear, most conferences and meetings are being postponed or cancelled. Some have taken to having conferences and meetings in a virtual setting, such as the recently ended American College of Cardiology/World Congress of Cardiology (ACC.20/WCC) conference. MIMS and the Asian Young Pharmacist Group (AYPG) took this opportunity to engage with pharmacists in the form of a Zoom meeting.